Engineering technology of implantable galvanic cells for silencing the bone-neural axis in gouty arthritis therapy Authors: Jie Cao, Nailin Yang, Fei Gong, Xi Wang, Xinyi Qiao, Xiaoxiao Pan, Qialu Du, Yichi Cai, Jie Wu, Yechen Huang, Yichen Wang, Zhihui Han, Liang Cheng Published: 2026 ABSTRACT Gouty arthritis faces multiple challenges, such as recalcitrance to cure and recurrent flares, owing to its intricate pathophysiological microenvironment. Recent studies have focused on urate reduction, pain relief, or anti-inflammation effects alone, which often fail to provide satisfactory results. To address these challenges, an implantable manganese platinum microscale galvanic cell (Mn@Pt micro-GC) is developed. This system utilizes the urate oxidase-like activity of platinum to degrade deposited monosodium urate crystals, while the Mn2+ and hydrogen gas work synergistically to effectively reversing the pro-inflammatory environment. In addition to decreasing the production of pain signals associated with gout, Mn@Pt micro-GC effectively inhibits pain signal transmission along the CXCL5-neuronal CXCR2-TRPA1 axis through continuous electrical stimulation. This multimodal treatment approach emphasizes the strong relationship between bone and nerve in gout, taking into account the importance of reducing uric acid, anti-inflammation, and pain relief in gout therapy, which has led to improved treatment results. Introduction Gouty arthritis is a type of inflammatory arthritis caused by hyperuricemia (HUA). The main cause of gout is excessive levels of uric acid (UA) in the blood, which leads to the formation and accumulation of monosodium urate (MSU) crystals in the joints and surrounding soft tissues, triggering inflammatory reactions1,2. The existing clinical treatments for gout involve providing temporary relief from inflammation and pain during acute attacks (colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids), as well as long-term reduction of UA levels by preventing its generation and reabsorption (allopurinol, febuxostat, and benzbromarone)3,4. Nevertheless, these methods may result in significant side effects, including cardiovascular diseases, liver and kidney dysfunction, and urinary tract stones5–7. Current studies have focused mostly on delivering exogenous urate oxidase to the body for treatment, which facilitates the decomposition of UA into soluble allantoin for removal from the body8–10. However, as an exogenous protein, urate oxidase provokes an immune response in the human body and is prone to hydrolysis and digestion by proteases11. Furthermore, the urate oxidase-catalyzed degradation of UA generates hydrogen peroxide (H2O2) as a byproduct12. The relatively closed internal environment and slow metabolism within the joint cavity increase the accumulation of H2O2, which intensifies inflammatory responses and exacerbates joint damage13. Previous studies have shown that platinum (Pt), as a precious metal, has good catalytic properties and can effectively degrade UA and decompose H2O2 simultaneously14,15. However, the catalase activity of Pt is limited due to its insufficient biological activity compared with that of catalase. Consequently, developing a self-cascade reaction platform that can boost the multifunctional enzyme activity of Pt may offer a strategy for treating gouty arthritis. There are densely distributed sensory nerves on the periosteum of healthy bones16–18. When bone inflammation or fracture occurs, these nerve cells on the periosteum transmit signals to the central nerve and sensory regions of the brain, resulting in pain19. This relevance, in which pathological conditions of abnormal bone cause peripheral nerve tissues to generate disease signals and transmit them to the higher-level nervous system, is referred as the bone-neural axis. C-X-C motif chemokine receptor 2 (CXCR2) is an important member of the G protein-coupled receptor (GPCR) family and is capable of binding to different CXC chemokines and initiating a range of complex signal transduction processes20. The excessive accumulation of MSU in the joint cavity promotes the release of multiple cytokines and chemokines (TNF-α, IL-1β, and CXCL5) by macrophages21,22. Among them, the release of C-X-C motif chemokine ligand 5 (CXCL5) activates CXCR2 expressed on nociceptive neurons and triggers transient receptor potential cation channel subfamily A member 1 (TRPA1) activation, leading to joint pain in gouty arthritis23. Therefore, targeting the CXCL5-neuronal CXCR2-TRPA1 axis to inhibit gouty pain-related signaling pathways may promote the treatment of gouty arthritis. Previous studies have reported that near-infrared light irradiation can stimulate nerve endings and produce a certain analgesic effect10. However, this effect is temporary, and prolonged use may harm the skin and mucous membranes. Electrical stimulation is a widely recognized and effective treatment method in clinical rehabilitation therapy24–27. It plays a significant role in promoting neuronal regeneration and functional recovery, as well as reducing nerve pain and muscle atrophy in the limbs28,29. Traditional electrical stimulation devices use output ports to connect electrode pads on the surface of the patient’s skin for treatment. To overcome the shortcomings of traditional electrical stimulation devices being bulky and inconvenient for treatment, various dressings or patches based on the galvanic cell principle have gradually been researched and applied30,31. These dressings or patches provided in situ electrical stimulation therapy to promote tissue repair and anti-inflammatory effects. However, few biomaterials based on galvanic cells are currently used to regulate and alleviate neuropathic pain. Moreover, in order to deliver effective electrical stimulation within the body, the implantable electrical stimulation devices have been gradually researched and developed32–34. Unfortunately, the use of toxic electrolyte in current implantable lithium batteries presents safety risks, and their strict packaging leads to a large size that makes in-situ implantation difficult35,36. Additionally, the use of transcutaneous wires can increase the risk of infection37. Hence, there is an urgent need to develop an implantable electrical stimulation device that can effectively provide electrical stimulation while being safe, non-toxic, small in volume, and minimizing the risk of infection. Herein, an implantable manganese platinum microscale galvanic cell (abbr. Mn@Pt micro-GC) is designed to treat gouty arthritis through an in-situ spontaneous metal replacement reaction of Pt onto the surface of manganese (Mn) microparticles (Fig. 1). Specifically, the Mn@Pt micro-GC exhibits urate oxidase-like activity due to the catalytic activity of Pt, allowing it to effectively eliminate accumulated MSU in the ankle joint and then decrease the secretion of CXCL5 from macrophages. Additionally, it could spontaneously undergo redox reactions in the electrolyte, generating hydrogen gas (H2) and manganese ions (Mn2+). Mn2+ further facilitates the elimination of H2O2 and improves the urate oxidase-catalase (UAO-CAT) self-cascade reaction. Furthermore, H2, which acts as a gentle endogenous gas38,39, quickly diffuses into tissues and cells to eliminate reactive oxygen species (ROS), modulates macrophage polarization, and decreases the secretion of pro-inflammatory factors, thereby further alleviating the inflammatory response. Through in-situ metal replacement reaction technology, the positive and negative electrodes of the Mn@Pt micro-GC are in direct contact, allowing it to react spontaneously in the tissue fluid of the joint cavity. This design effectively avoids the need for toxic electrolytes and transcutaneous wires. Compared with conventional batteries, Mn@Pt micro-GC possesses a smaller volume and could be injected in-situ at the site of pain, enabling precise electrical stimulation in the body. In addition to reducing the production of the irritant CXCL5 from macrophages through the degradation of MSU, the continuous electrical stimulation from Mn@Pt micro-GC diminishes the ability of CXCL5 to bind with CXCR2, thereby reducing the activation of TRPA1 and the influx of Ca2+ and inhibiting signal transmission through the CXCL5-neuronal CXCR2-TRPA1 axis. Additionally, its suppression of the JAK-STAT signaling pathway alleviates endoplasmic reticulum stress, further reducing the outflow of Ca2+ from the endoplasmic reticulum. This approach effectively inhibits the CXCL5-neuronal CXCR2-TRPA1 axis and the transmission of pain signals, helping to relieve joint pain associated with gout and supporting the treatment of gouty arthritis. Overall, Mn@Pt micro-GC offers an approach for gout management that integrates UA clearance, anti-inflammatory effects, and pain relief.Fig. 1The scheme illustrates the therapeutic mechanism of Mn@Pt micro-GC aganist gouty arthritis.Schematic illustration of an implantable manganese platinum microscale galvanic cell (Mn@Pt micro-GC) to simultaneously achieve urate reduction, pain relief and anti-inflammation for the treatment of gouty arthritis (created in BioRender. Fei, G. (2026) https://BioRender.com/vpz5eh7). The scheme illustrates the therapeutic mechanism of Mn@Pt micro-GC aganist gouty arthritis. Schematic illustration of an implantable manganese platinum microscale galvanic cell (Mn@Pt micro-GC) to simultaneously achieve urate reduction, pain relief and anti-inflammation for the treatment of gouty arthritis (created in BioRender. Fei, G. (2026) https://BioRender.com/vpz5eh7). Results Synthesis, screening and characterization of Mn@Pt micro-GC Manganese platinum microscale galvanic cell (Mn@Pt micro-GC) was synthesized using an in-situ spontaneous metal replacement method40,41, wherein Mn microparticles were immersed in a chloroplatinic acid (PtCl62−) ethanol solution to enable surface deposition of Pt through redox-driven displacement. The obtained Mn@Pt micro-GC experienced a spontaneous redox reaction in the electrolyte (Fig. 2A). Specifically, electrons (e-) moved from the negative electrode (Mn electrode, Mn − 2e- = Mn2+) to the positive electrode (Pt electrode, 2H2O + 2e- = H2 + 2OH-) and then returned to the negative electrode through the electrolyte, creating a closed circuit that led to the etching of Mn and the generation of H2. Considering the impact of the Mn particle size on the reaction activity of the galvanic cell, the generation rate of H2 was considered as an evaluation criterion to screen suitable-sized Mn particles. Two sizes of the commercial Mn microparticles (large size: ~50 μm and small size: ~10 μm) were selected. After reacting with an equal amount of PtCl62- to synthesize Mn@Pt micro-GC, the production rate of H2 was compared. The Mn@Pt micro-GC (referred to as Mn@Pt in all figures) obtained with a smaller Mn produced H2 more quickly with greater amounts (Supplementary Fig. 1), indicating their higher reaction activity. Consequently, to achieve long-term reaction and prevent potential tissue damage caused by the intense reaction of Mn@Pt micro-GC, larger Mn microparticles (~50 μm) were used to synthesize the Mn@Pt micro-GC for further investigation.Fig. 2Characterization, electrochemical performance, release, and catalytic degradation properties of the Mn@Pt micro-GC.A Schematic diagram of the preparation and redox reaction of the Mn@Pt micro-GC. B SEM images and schematic diagrams of Mn and Mn@Pt micro-GC with various mass ratios (0.10%, 0.16%, 0.2%, and 0.48%). C Voltage and D electric current variation of Mn@Pt micro-GC with different mass ratios within 3000 s. E Tafel curves and F corrosion potentials of Mn@Pt micro-GC with different mass ratios (n = 3 independent experiments). G UA scavenging ability of different treatment groups, including Mn, Pt, Mn+Pt, and Mn@Pt micro-GC (n = 3 independent experiments). Insert a schematic diagram of the reaction process. H XPS spectra of Mn@Pt micro-GC before and after reaction with UA. I Mn2+ and H2 release from the Mn@Pt micro-GC (n = 3 independent experiments). J H2O2 elimination capacity of Mn, Pt, or Mn@Pt micro-GC detected by titanium oxysulfate colorimetry. K O2 generation after the Mn, Pt, or Mn@Pt micro-GC reacted with H2O2. UV-vis absorbance spectra of L •ABTS+ and M oxTMB after incubation with different amounts of Mn@Pt micro-GC for 30 min. Insert photographs and schematic diagrams of the reaction. N) Schematic diagram of the functions of different components in the Mn@Pt micro-GC. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Schematic diagrams of A, B, and N were created in BioRender. Fei, G. (2026) https://BioRender.com/f2pj63x. Characterization, electrochemical performance, release, and catalytic degradation properties of the Mn@Pt micro-GC. A Schematic diagram of the preparation and redox reaction of the Mn@Pt micro-GC. B SEM images and schematic diagrams of Mn and Mn@Pt micro-GC with various mass ratios (0.10%, 0.16%, 0.2%, and 0.48%). C Voltage and D electric current variation of Mn@Pt micro-GC with different mass ratios within 3000 s. E Tafel curves and F corrosion potentials of Mn@Pt micro-GC with different mass ratios (n = 3 independent experiments). G UA scavenging ability of different treatment groups, including Mn, Pt, Mn+Pt, and Mn@Pt micro-GC (n = 3 independent experiments). Insert a schematic diagram of the reaction process. H XPS spectra of Mn@Pt micro-GC before and after reaction with UA. I Mn2+ and H2 release from the Mn@Pt micro-GC (n = 3 independent experiments). J H2O2 elimination capacity of Mn, Pt, or Mn@Pt micro-GC detected by titanium oxysulfate colorimetry. K O2 generation after the Mn, Pt, or Mn@Pt micro-GC reacted with H2O2. UV-vis absorbance spectra of L •ABTS+ and M oxTMB after incubation with different amounts of Mn@Pt micro-GC for 30 min. Insert photographs and schematic diagrams of the reaction. N) Schematic diagram of the functions of different components in the Mn@Pt micro-GC. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Schematic diagrams of A, B, and N were created in BioRender. Fei, G. (2026) https://BioRender.com/f2pj63x. The electrochemical performance of the Mn@Pt micro-GC was also affected by the ratio of the positive and negative electrodes. Therefore, various concentrations of PtCl62- were reacted with Mn to create Mn@Pt micro-GC with different mass ratios (m(attached amount of Pt)/m(Mn) = 0.10%, 0.16%, 0.20%, and 0.48%). X-ray diffraction (XRD) patterns revealed the appearance of Pt peaks (JCPDS No. 04-0802), suggesting that Pt was successfully in-situ displaced on the surface of the Mn (Supplementary Fig. 2). Scanning electron microscopy (SEM) images revealed the uniform distribution of Pt on the surface of Mn (Pt was indicated by arrows), which revealed that the coverage of Pt on the Mn became denser as the mass ratio increased (Fig. 2B). Subsequently, the variations of the voltage and current of Mn@Pt micro-GC with different Pt contents were continuously monitored within 50 min via an electrochemical workstation. As the mass ratio increased, the voltage generated by the Mn@Pt micro-GC weakened and exhibited enhanced instability over time (Fig. 2C, Supplementary Fig. 3). However, the intermittency of current generation was not influenced by different mass ratios (Fig. 2D). The spontaneous reaction of the Mn@Pt micro-GC was also an electrochemical corrosion process, where a higher corrosion potential reduces the likelihood of oxidative corrosion reactions and H2 production. The Tafel curve and analysis results suggested that increasing the content of Pt enhanced the electrochemical corrosion processes, indicating that ~0.48% mass ratios of Mn@Pt micro-GC resulted in stronger reaction activity (Fig. 2E, F). As a result, with increasing mass ratio, Mn@Pt micro-GC possessed greater potential instability and faster reaction kinetics. To further investigate the effects of different Pt levels on the therapeutic effect of Mn@Pt micro-GC on gout, the UA and ROS scavenging abilities of the Mn@Pt micro-GC with different mass ratios were compared. The ROS scavenging capacity of the Mn@Pt micro-GC was evaluated by using 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radicals (•ABTS+, with a characteristic absorption peak at ~738 nm) and H2O2. As a result, Mn@Pt micro-GC with mass ratios of 0.20% and 0.48% were superior in terms of ROS removal (Supplementary Fig. 4B, C). However, the ability of Mn@Pt micro-GC to scavenge UA was not directly proportional to the Pt content, as the ~ 0.20% mass ratio of Mn@Pt micro-GC resulted in better UA degradability after 4 h than the other mass ratios did, even reaching ~93.52% at 24 h (Supplementary Fig. 4A). Furthermore, while the 0.20% and 0.48% mass ratios of Mn@Pt micro-GC demonstrated better H2O2 decomposition ability, the oxygen (O2) generation of the 0.48% mass ratio was lower than that of the other groups (Supplementary Fig. 4D). The decomposition of UA necessitated the presence of O2, which clarified why the UA clearance effect of the 0.48% mass ratio of Mn@Pt micro-GC was not strong. Hence, after the electrochemical properties and catalytic degradation capabilities of the Mn@Pt micro-GC were comprehensively evaluated, a 0.20% mass ratio of Mn@Pt micro-GC was chosen for further investigation. EDS element mapping further illustrated the distribution of Mn and Pt in Mn@Pt micro-GC (Supplementary Fig. 5A). The X-ray photoelectron spectroscopy (XPS) results indicated that the Mn2p3/2 peak in Mn@Pt micro-GC was blue-shifted compared with that in Mn and exhibited a strong signal from Mn (Ⅱ), which further confirmed the electron loss and oxidation of Mn at the negative electrode, while H2O gained electrons and was reduced to generate H2 (Supplementary Fig. 5B). These findings implied that generating functional Mn@Pt micro-GC through an in-situ galvanic replacement technique was feasible. To more thoroughly demonstrate the electrical discharge capability of the Mn@Pt micro-GC, its voltage changes were monitored over a 60-day period. On day 60, the voltage remained at ~315.38 mV, indicating that the Mn@Pt micro-GC could sustain long-term and continuous discharge in vitro (Supplementary Fig. 6). Compared with using physiological saline as the reaction medium, the Mn@Pt micro-GC exhibited a more stable voltage trend in the joint simulation fluid, and the Tafel curves indicated a weaker electrochemical corrosion process (Supplementary Fig. 7). Additionally, whether in a three-electrode system (~608.18 mV) or a two-electrode system (~605.47 mV), the open-circuit voltages of the Mn@Pt micro-GC were similar and showed comparable trends (Supplementary Fig. 8A). Moreover, the current of the Mn@Pt micro-GC fluctuated over time in both the two-electrode system and current source meter (Supplementary Fig. 8B). Catalytic degradation and antioxidant effects of Mn@Pt micro-GC To further demonstrate the catalytic degradation capability of the Mn@Pt micro-GC, Mn, Pt, and a mixture of Mn and Pt were used as controls. The UA clearance results showed that although Pt and Mn+Pt also exhibited urate oxidase-like activity, their clearance efficiency was weaker than that of Mn@Pt micro-GC (Fig. 2G). It was hypothesized that the Mn2+ produced from the Mn@Pt micro-GC enhanced its ability to decompose H2O2 and generate O2 under identical conditions (Mn2+ + H2O2 + 2OH- → MnO2 + 2H2O, MnO2 + H2O2 + 2H+ → Mn2+ + O2 + 2H2O), thus facilitating the UA → H2O2 → O2 cascade reaction (Fig. 2I–K, Supplementary Fig. 9, 10). XPS analysis of the Mn@Pt micro-GC after its reaction with UA revealed a decrease in the intensity of the Pt peak, suggesting that the Pt in the Mn@Pt micro-GC was indeed the main catalyst for the degradation of UA and fell off during this reaction. Moreover, the signal of Mn (Ⅱ) at the Mn3s in the Mn@Pt micro-GC increased, which supported the previous hypothesis (Fig. 2H). Moreover, compared with Pt, Mn@Pt micro-GC exhibited superior enzymatic kinetic properties and had a stronger affinity for UA, as its Michaelis constant (Km, which is the substrate concentration at half the maximum reaction rate) was lower than that of Pt (Supplementary Fig. 11). H2 is widely utilized as an anti-inflammation agent for its capacity to scavenge ROS and combat oxidative stress42–44. Thus, the release of H2 from Mn@Pt micro-GC was evaluated when they were immersed in an aqueous solution and spontaneously subjected to electrochemical corrosion. Owing to the influence of the Mn size and mass ratio of the positive and negative electrodes, H2 was released long-term and continuously from the Mn@Pt micro-GC (0.20%) ( ~ 56.5 μmol for 24 h), which was beneficial for long-term ROS elimination (Fig. 2I). Subsequently, hydroxyl radical (•OH) and •ABTS⁺ were employed to evaluate the antioxidant activity of the Mn@Pt micro-GC. The •OH was formed by the Fenton reaction (H2O2/Fe2+) and was able to oxidize the 3, 3’, 5, 5’-tetramethylbenzidine (TMB) probe (colorless) to oxTMB (with a characteristic absorption peak at 652 nm). As a result, the colors of both free radicals decreased, and their characteristic peaks dropped with increasing concentrations of Mn@Pt micro-GC (Fig. 2L, M, Supplementary Fig. 12), indicating their positive antioxidant performance. Above all, the urate oxidase-like activity of the Mn@Pt micro-GC was derived from the Pt catalyst. Due to the ability of galvanic cells to spontaneously undergo redox reactions and generate flowing electrons in water, the H2 and Mn2+ were produced accordingly. Among them, Mn2+ eliminated H2O2, a byproduct of UA decomposition, facilitating the cascade reactions, while H2 effectively scavenged ROS and exerted antioxidant effects (Fig. 2N). This Mn@Pt micro-GC simultaneously addressed multiple issues associated with gout, potentially acting as a bimetallic platform for the effective treatment of gouty arthritis. Cytocompatibility, cell viability, and in intro ROS elimination of Mn@Pt micro-GC Favorable biocompatibility is essential for effectively managing gouty arthritis10,13. Given that inflammation, bone tissue and peripheral nerves are involved in the gout-affected joint, mouse mononuclear macrophage leukemia RAW264.7 cells, mouse embryonic osteoblast precursor cells (MC3T3-E1), and rat adrenal pheochromocytoma (PC-12) cells were co-cultured with Mn@Pt micro-GC for 24 h, respectively. The standard methyl thiazolyl tetrazolium (MTT) assay revealed no obvious cell death even at a concentration of 100 μg/mL, demonstrating the good cytocompatibility of Mn@Pt micro-GC (Supplementary Fig. 13). When the level of UA exceeds the metabolic capacity of the body, insoluble crystals form and accumulate in the joints, leading to joint and surrounding tissue damage45,46. Moreover, these crystals trigger an inflammatory response, and the H2O2 produced from their decomposition worsens inflammation47. Accordingly, it was important to explore the cellular protection and anti-inflammatory properties of Mn@Pt micro-GC (Fig. 3A). Following treatment with insoluble UA crystals, a significant number of RAW264.7 cells died. However, the introduction of Mn@Pt micro-GC effectively improved cell survival, increasing the rate to ~80%, which was superior to that of the UA/Mn or UA/Pt groups (Fig. 3B). Then, [Ru(dpp)3]Cl2 was utilized as an O2 luminescence detection probe, which can be quenched by molecular oxygen, to evaluate the ability of Mn@Pt micro-GC to decompose H2O2. Confocal laser scanning microscopy (CLSM) images and statistical analysis revealed that the H2O2/Mn@Pt group presented the weakest fluorescence signal of [Ru(dpp)3]Cl2, while the fluorescence intensity in the other control groups did not markedly decrease (Fig. 3C, Supplementary Fig. 14). These findings indicated that Mn@Pt micro-GC effectively degraded UA through the urate oxidase-like activity of Pt and produced Mn2+ to clear H2O2, a byproduct of UA degradation, highlighting its good ability to protect cells. Additionally, the antioxidant effect of Mn@Pt micro-GC was confirmed via the use of a 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) probe, which reacts with ROS to generate DCF with green fluorescence48. After RAW264.7 cells were stimulated with lipopolysaccharide (LPS) to produce excess ROS, CLSM images revealed that the green fluorescence in the LPS/Mn and LPS/Pt groups was slightly weakened, while the LPS/Mn@Pt group exhibited almost no green fluorescence, similar to the Ctrl group (Fig. 3D, E). Flow cytometry analysis also revealed similar results (Fig. 3F, G), indicating that the H2 produced from the Mn@Pt micro-GC effectively eliminated ROS and alleviated cellular oxidative stress. In addition, the increase in ROS levels stimulated by MSU could also be effectively suppressed by Mn@Pt micro-GC (Supplementary Fig. 15A, B), indicating that besides the antioxidant effect of H2 in the inflammatory environment, the clearance of MSU by Mn@Pt micro-GC also alleviated gout-related inflammatory responses to some extent. Thus, the Mn@Pt micro-GC demonstrated good biocompatibility, protecting cells from damage and oxidative stress, which supported its potential application in gout treatment.Fig. 3UA degradation, H2O2 clearance, and anti-inflammatory properties of the Mn@Pt micro-GC.A Schematic diagram of the ability of Mn@Pt micro-GC to protect cells and scavenge H2O2 and ROS, while regulating macrophage polarization (created in BioRender. Fei, G. (2026) https://BioRender.com/1anig13). B Survival rate of RAW264.7 cells after different treatments, including Ctrl, UA, UA/Mn, UA/Pt, and UA/Mn@Pt (n = 3 independent experiments). C O2 levels in RAW 264.7 cells treated with different groups, including Ctrl, H2O2, H2O2/Mn, H2O2/ Pt, and H2O2/Mn@Pt (orange, [Ru(dpp)3]Cl2; blue, DAPI). D Representative fluorescence staining images (green, DCF; blue, DAPI). F Flow cytometric examination, and E, G corresponding statistical analysis (n = 5 independent experiments, n = 3 independent experiments) of intracellular ROS levels in RAW264.7 cells treated with different groups after LPS (250 ng/mL) stimulation for 12 h, including Ctrl, LPS, LPS/Mn, LPS/Pt, and LPS/Mn@Pt. H–K TNF-α, IL-6, IL-10, and TGF-β levels in RAW 264.7 cells subjected to different treatments (n = 4 independent experiments). L, M Statistical analysis (n = 5 independent experiments) and N, O representative fluorescence staining images of macrophage markers expressed by RAW264.7 cells after different treatments (red, iNOS; green, Arg-1; green or orange, Phalloidin; blue, DAPI). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test, and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. UA degradation, H2O2 clearance, and anti-inflammatory properties of the Mn@Pt micro-GC. A Schematic diagram of the ability of Mn@Pt micro-GC to protect cells and scavenge H2O2 and ROS, while regulating macrophage polarization (created in BioRender. Fei, G. (2026) https://BioRender.com/1anig13). B Survival rate of RAW264.7 cells after different treatments, including Ctrl, UA, UA/Mn, UA/Pt, and UA/Mn@Pt (n = 3 independent experiments). C O2 levels in RAW 264.7 cells treated with different groups, including Ctrl, H2O2, H2O2/Mn, H2O2/ Pt, and H2O2/Mn@Pt (orange, [Ru(dpp)3]Cl2; blue, DAPI). D Representative fluorescence staining images (green, DCF; blue, DAPI). F Flow cytometric examination, and E, G corresponding statistical analysis (n = 5 independent experiments, n = 3 independent experiments) of intracellular ROS levels in RAW264.7 cells treated with different groups after LPS (250 ng/mL) stimulation for 12 h, including Ctrl, LPS, LPS/Mn, LPS/Pt, and LPS/Mn@Pt. H–K TNF-α, IL-6, IL-10, and TGF-β levels in RAW 264.7 cells subjected to different treatments (n = 4 independent experiments). L, M Statistical analysis (n = 5 independent experiments) and N, O representative fluorescence staining images of macrophage markers expressed by RAW264.7 cells after different treatments (red, iNOS; green, Arg-1; green or orange, Phalloidin; blue, DAPI). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test, and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Mn@Pt micro-GC regulates macrophages phenotype and cytokine release During gouty arthritis, macrophages are triggered to release a large amount of inflammatory substances, which results in swelling, nerve irritation and leads to joint deterioration and deformity if left untreated for prolonged periods49–51. Therefore, enzyme-linked immunosorbent assay (ELISA) kits were used to measure the levels of inflammatory factors produced by macrophages following different treatments. Under LPS stimulation, the levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), were increased, but these levels significantly decreased after Mn@Pt micro-GC treatment (Fig. 3H, I). In contrast, LPS suppressed the release of anti-inflammatory factors such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), while Mn@Pt micro-GC treatment reversed this effect, facilitating a shift in the macrophage microenvironment from a pro-inflammatory to an anti-inflammatory state (Fig. 3J, K). In addition, the release of inflammatory factors is often accompanied by changes in the macrophage phenotype, leading to the activation of classically activated (M1) macrophages52. To assess this, M1 macrophages were labeled with inducible nitric oxide synthase (iNOS, red), and alternatively activated (M2) macrophages were labeled with arginase-1 (Arg-1, green). Confocal imaging revealed that after Mn@Pt micro-GC treatment, there was a significant reduction in red fluorescence and a notable increase in green fluorescence compared with those in the LPS/Mn and LPS/Pt groups, indicating that Mn@Pt micro-GC successfully facilitated the transition from the M1 inflammatory phenotype to the M2 anti-inflammatory phenotype (Fig. 3L–O). In addition, this finding was validated using CD80 to label M1 macrophages, which revealed a reduction in the number of M1 macrophages following Mn@Pt micro-GC treatment (Supplementary Fig. 16). Similarly, the ability of Mn@Pt micro-GC to degrade MSU also inhibited the high expression of iNOS induced by MSU-stimulated macrophages and promoted the increased levels of Arg-1 in macrophages (Supplementary Fig. 15C–F). The ability of Mn@Pt micro-GC to regulate macrophage phenotypes and reduce the secretion of inflammatory factors was attributed to the long-term and continuous production of H2 with anti-inflammatory effects as well as its own urate oxidase-like activity, suggesting that Mn@Pt micro-GC holds great promise as a candidate for the treatment of gouty arthritis. Mn@Pt micro-GC-induced electrical stimulation alleviates neuropathic pain and its underlying mechanism To better understand the discharge behavior of Mn@Pt micro-GC, its voltage variations at the cellular level were assessed via an electrochemical workstation. The findings revealed that the discharge of Mn@Pt micro-GC in cells increased as the concentration of it rose, and the lowest concentration of Mn@Pt micro-GC (100 μg/mL) achieved a voltage change of ~16.3 mV within 3000 s (Fig. 4A), indicating that Mn@Pt micro-GC provides long-term electrical stimulation to these cells. Additionally, this change led to modifications in the cell membrane potential, which sustained a high charge state on the cell surface (Fig. 4B, Supplementary Fig. 17). In addition to the accumulation of MSU and inflammatory responses, gout attacks also involve severe pain, which arises from the activation of the CXCL5-neuronal CXCR2-TRPA1 axis23. As a key substance that stimulated this axis, MSU was introduced into RAW264.7 cells. Western blot (WB) results indicated that the expression of CXCL5 increased in the MSU group, while the MSU/Pt and MSU/Mn@Pt groups improved this phenomenon (Fig. 4C, Supplementary Fig. 18A). Then, the supernatants of RAW264.7 cells from different treatment groups were collected as conditioned medium (CM) to culture PC-12 cells individually. Both the MSU/Pt-CM and MSU/Mn@Pt-CM groups presented reduced expression of CXCR2 and TRPA1 (Fig. 4C, Supplementary Fig. 18B, C). TRPA1 is a non-selective cation channel that allows the passage of Ca2+ and is a key target for pain. Hence, Fluo 4-AM probe was utilized to measure Ca2+ influx. Flow cytometry results aligned with the WB results, revealing a notable increase in Ca2+ influx in the MSU-CM group, while the MSU/Mn@Pt-CM group exhibited the most pronounced reduction in Ca2+ influx (Supplementary Fig. 18D, E). This reduction may be attributed to the effective elimination of MSU by the Pt catalyst, which decreased the secretion of CXCL5 from RAW264.7 cells and subsequently alleviated the activation of the CXCR2-TRPA1 axis, thereby decreasing calcium influx.Fig. 4Mn@Pt micro-GC -induced pain relief.A Relative voltage variation curves after introducing different concentrations of Mn@Pt micro-GC to PC-12 cells. Insert schematic diagram of the reaction process. B Representative fluorescence images of the membrane potential of PC-12 cells treated with different amounts of Mn@Pt micro-GC (red, RH414; DAPI, blue). C WB results showing that Mn@Pt micro-GC downregulated the CXCL5-neuronal CXCR2-TRPA1 axis. Insert schematic diagram of the experimental process. D Schematic diagram of the electricity released from Mn@Pt micro-GC compared with that from external electrical stimulation. E Volcano plots of differentially expressed genes. Some significant genes are marked in red. F Heat map of genes differentially expressed between different groups. G GO analysis and H KEGG analysis of pathways enriched by the differentially expressed genes. I Cytokine-cytokine receptor interaction according to GSEA. J TRPA1 and CXCR2 expression of PC-12 cells after different treatments was measured using immunoblotting. GAPDH served as a control for protein loading. K Flow cytometric examination of Ca2+ influx in PC-12 cells subjected to different treatments. L Schematic diagram of the mechanisms for Mn@Pt micro-GC-induced pain relief. Differential expression analysis was performed using DESeq2. The Wald test was applied, and p-values were adjusted using the Benjamini-Hochberg method (E). The hypergeometric test was performed to identify pathways significantly enriched among the DEGs (H). The permutation test (1000 phenotype permutations) was used to calculate the NES and FDR (I). Source data are provided as a Source Data file. Schematic diagrams of A, C, D, and L were created in BioRender. Fei, G. (2026) https://BioRender.com/jv5n2i6. Mn@Pt micro-GC -induced pain relief. A Relative voltage variation curves after introducing different concentrations of Mn@Pt micro-GC to PC-12 cells. Insert schematic diagram of the reaction process. B Representative fluorescence images of the membrane potential of PC-12 cells treated with different amounts of Mn@Pt micro-GC (red, RH414; DAPI, blue). C WB results showing that Mn@Pt micro-GC downregulated the CXCL5-neuronal CXCR2-TRPA1 axis. Insert schematic diagram of the experimental process. D Schematic diagram of the electricity released from Mn@Pt micro-GC compared with that from external electrical stimulation. E Volcano plots of differentially expressed genes. Some significant genes are marked in red. F Heat map of genes differentially expressed between different groups. G GO analysis and H KEGG analysis of pathways enriched by the differentially expressed genes. I Cytokine-cytokine receptor interaction according to GSEA. J TRPA1 and CXCR2 expression of PC-12 cells after different treatments was measured using immunoblotting. GAPDH served as a control for protein loading. K Flow cytometric examination of Ca2+ influx in PC-12 cells subjected to different treatments. L Schematic diagram of the mechanisms for Mn@Pt micro-GC-induced pain relief. Differential expression analysis was performed using DESeq2. The Wald test was applied, and p-values were adjusted using the Benjamini-Hochberg method (E). The hypergeometric test was performed to identify pathways significantly enriched among the DEGs (H). The permutation test (1000 phenotype permutations) was used to calculate the NES and FDR (I). Source data are provided as a Source Data file. Schematic diagrams of A, C, D, and L were created in BioRender. Fei, G. (2026) https://BioRender.com/jv5n2i6. Especially, the Mn@Pt micro-GC demonstrated a more significant CXCL5-neuronal CXCR2-TRPA1 axis inhibition effect than Pt did, suggesting that an additional component played a role in this process, even as Pt diminished the source of stimulation. Since electrical stimulation has been reported to alleviate neuropathic pain, we speculated that the electrical stimulation produced by Mn@Pt micro-GC itself also contributed to the inhibition of the CXCL5-neuronal CXCR2-TRPA1 axis. Therefore, we added external electrical stimulation (ES group) as a control and investigated the potential mechanism by which the Mn@Pt micro-GC inhibited neuropathic pain through RNA sequencing (Fig. 4D). The volcano plot and gene heatmap results revealed that the genes in the MSU-CM/Mn@Pt group or MSU-CM/ES group were significantly different from those in the MSU-CM group (Fig. 4E, F, Supplementary Fig. 19A), including signal transduction-related phospholipase C beta 1 (Plcb1), G protein-coupled receptor activation-related F2R like trypsin receptor 1 (F2rl1), inflammation-related interleukin 1 receptor accessory protein (Il1rap), neuropeptide-related CGRP receptor component (Crcp), and Ca2+ influx-related calcium voltage-gated channel subunit alpha1 D (Cacna1d), whose expression was significantly downregulated. In contrast, genes related to neuronal development and function, such as neural cell adhesion molecule 2 (Ncam2), tetratricopeptide repeat domain 28 (Ttc28), atonal bHLH transcription factor 8 (Atoh8), and ciliary neurotrophic factor (Cntf), were significantly upregulated. These results indicated that electrical stimulation effectively inhibited G protein-coupled receptor-related signaling, reduced inflammatory responses, and promoted neuronal growth and development. To annotate the functions of the differentially expressed genes, gene ontology (GO) analysis was conducted. Compared with those in the MSU-CM group, G protein-coupled purinergic nucleotide receptor activity (GO:0045028), response to cytokines (GO:0034097), and response to endoplasmic reticulum stress (GO:0034976) were significantly downregulated after Mn@Pt micro-GC treatment (Fig. 4G). Subsequently, the kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis suggested that the protein processing in the endoplasmic reticulum and cytokine-cytokine receptor interaction were significantly downregulated among the 18 significantly altered pathways. In addition to these signaling pathways, the JAK-STAT signaling pathway was also decreased (Fig. 4H). Similarly, the MSU-CM/ES group also presented a decrease in cytokine activity (GO:0005125), response to endoplasmic reticulum stress (GO:0034097), cytokine-cytokine receptor interaction, and the JAK-STAT signaling pathway (Supplementary Fig. 19B, C). Previous study has shown that electroacupuncture treatment could inhibit the overexpression of CXCR2 mediated by STAT3 to alleviate acute gouty arthritis53, which also supported our findings. Next, the gene set enrichment analysis (GSEA) of the entire gene sets further revealed that Cxcr2 was downregulated in the cytokine-cytokine receptor interaction (Fig. 4I), which was also observed in the MSU-CM/ES group (Supplementary Fig. 19D). These results indicated that the electrical stimulation produced by Mn@Pt micro-GC primarily hindered the transmission of pain signals by weakening the ability of CXCL5 to interact with CXCR2. Moreover, it also reduced the production of various second messengers, such as inositol trisphosphate (IP3) and diacylglycerol (DG) by inhibiting Plcb1, which downregulated the JAK-STAT signaling pathway, alleviated endoplasmic reticulum stress, and decreased the release of Ca2+ from the endoplasmic reticulum. This inhibitory effect produced by electrical stimulation significantly attenuated the combination of CXCL5 and CXCR2, thereby reducing the activation of CXCR2 and TRPA1, which effectively relieved the phenomenon of Ca2+ influx. Compared with intermittent external electrical stimulation, continuous electrical stimulation of the Mn@Pt micro-GC exhibited a better inhibitory effect (Fig. 4J, K, Supplementary Fig. 20A–C). To further confirm the specificity of the sustained electrical stimulation released by the Mn@Pt micro-GC for pain relief, we included a physical mixture group of Mn+Pt for additional comparison. Compared with the Mn@Pt micro-GC or ES treatment, the MSU-CM/Mn+Pt treatment group did not produce an inhibitory effect on Ca2+ influx (Supplementary Fig. 20D, E). Importantly, the inhibition of Ca2+ influx by Mn or Pt was based on their ability to degrade MSU in our previous studies, thereby reducing the secretion of CXCL5 (Fig. 4C, Supplementary Fig. 18). However, under equal CXCL5 treatment conditions, the combined treatment of Mn and Pt failed to produce a similar effect. These results confirmed the significant role of the electrical stimulation released by Mn@Pt micro-GC in suppressing the CXCL5-neuronal CXCR2-TRPA1 axis. Thus, on the one hand, Mn@Pt micro-GC reduced the production of CXCL5 by degrading MSU, thereby alleviating the activation of the CXCL5-neuronal CXCR2-TRPA1 axis at its source. On the other hand, the sustained electrical stimulation produced by Mn@Pt micro-GC weakened the binding ability between CXCL5 and CXCR2, reducing the activation of TRPA1 and inhibiting Ca2+ influx. Furthermore, the inhibition of the JAK-STAT signaling pathway by Mn@Pt micro-GC further decreased the release of Ca2+ from the endoplasmic reticulum (Fig. 4L). This dual strategy of targeting the source of stimulation and blocking pain signal transmission may be beneficial for treating gouty arthritis. Therapeutic evaluation of Mn@Pt micro-GC treatments in acute gouty arthritis To explore the therapeutic effects of Mn@Pt micro-GC, MSU was injected into the ankle joint cavity of six-week-old sprague dawley (SD) rats to establish an acute gouty arthritis model (AGA), followed by corresponding treatments (Fig. 5A). The treatments included Sham (intra-articular injection of normal saline), AGA (intra-articular injection of MSU), AGA/Mn (intra-articular injection of MSU and Mn), AGA/Pt (intra-articular injection of MSU and Pt), AGA/Mn@Pt 1’ (intra-articular injection of MSU and Mn@Pt micro-GC (1 mg/mL)), and AGA/Mn@Pt 5’ (intra-articular injection of MSU and Mn@Pt micro-GC (5 mg/mL)). Measurements of UA levels in the serum at 6 h and 24 h revealed that both the AGA/Pt group and the AGA/Mn@Pt group effectively lowered UA levels in the rats, with the AGA/Mn@Pt 5’ group demonstrating the most significant UA clearance (Fig. 5B). These findings suggested that Pt endowed a superior UA degradability to that of Mn@Pt micro-GC, while the Mn2+ produced by the spontaneous reaction of Mn@Pt micro-GC enhanced the breakdown of H2O2, facilitating cascade reactions that led to more effective clearance of UA than that of pure Pt particles.Fig. 5Therapeutic evaluation of Mn@Pt micro-GC in AGA rats.A Schematic illustration of the therapeutic procedure used in the animal experiments (created in BioRender. Fei, G. (2026) https://BioRender.com/qurbiq8). B Effects of different treatments on lowering serum UA levels in AGA rats (n = 4 samples). C Diameter of the ankle joints in AGA rats treated with Mn, Pt, Mn@Pt 1’, or Mn@Pt 5’ (n = 4 samples). D Gait analysis of AGA rats at 6 h and 24 h after administration of Mn, Pt, Mn@Pt 1’, or Mn@Pt 5’. E Infrared thermographic images of AGA rats after different treatments. F Micro-CT images of the ankle joints of rats subjected to different treatments. G BMD and H Tb.Sp of the ankle joints in the different groups after treatment (n = 4 samples). I H&E and SO/FG images of the ankle joints from different treatment groups. J Immunohistochemical staining images of TNF-α and IL-10 in the tali after administration of different treatments. K Representative images and L, M statistical analysis of immunofluorescence staining for iNOS (red) and Arg-1 (green) in the ankle joints from various treatment groups (n = 5 samples). N–Q Hepatic and renal function tests of AGA rats at 24 h after administration, including AST, ALT, BUN, and Cr (n = 4 samples). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Therapeutic evaluation of Mn@Pt micro-GC in AGA rats. A Schematic illustration of the therapeutic procedure used in the animal experiments (created in BioRender. Fei, G. (2026) https://BioRender.com/qurbiq8). B Effects of different treatments on lowering serum UA levels in AGA rats (n = 4 samples). C Diameter of the ankle joints in AGA rats treated with Mn, Pt, Mn@Pt 1’, or Mn@Pt 5’ (n = 4 samples). D Gait analysis of AGA rats at 6 h and 24 h after administration of Mn, Pt, Mn@Pt 1’, or Mn@Pt 5’. E Infrared thermographic images of AGA rats after different treatments. F Micro-CT images of the ankle joints of rats subjected to different treatments. G BMD and H Tb.Sp of the ankle joints in the different groups after treatment (n = 4 samples). I H&E and SO/FG images of the ankle joints from different treatment groups. J Immunohistochemical staining images of TNF-α and IL-10 in the tali after administration of different treatments. K Representative images and L, M statistical analysis of immunofluorescence staining for iNOS (red) and Arg-1 (green) in the ankle joints from various treatment groups (n = 5 samples). N–Q Hepatic and renal function tests of AGA rats at 24 h after administration, including AST, ALT, BUN, and Cr (n = 4 samples). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Following the administration of MSU, the rats in the AGA group exhibited the most significant ankle swelling, the shortest step and stride lengths, the longest front/hind paw imprints, and the highest ankle joint temperature, which reached 34.2 °C within 24 h. Meanwhile, the MSU also led to severe bone erosion and deformation in the ankle joints of the rats (Fig. 5C–H, Supplementary Figs. 21, 22). These results reflected the intense pain, inflammatory response, and bone damage caused by gout. However, after Mn@Pt 5’ treatment, ankle swelling, fever, and their stride gradually normalized in the rats. At 24 h, the bone tissue condition and bone parameters of these rats were nearly indistinguishable from those of the Sham group. While Pt or Mn@Pt 1’ treatment also provided some relief to acute gout, they were not as effective as Mn@Pt 5’ in treatment. Subsequently, hematoxylin-eosin (H&E) staining revealed that the AGA group exhibited significant tissue injury in the talus, with safranin O/fast green (SO/FG) revealing destruction of both the cartilage layer (red) and the collagen fibers (blue) at the injury site. However, under Mn@Pt 5’ treatment, the ankle joint tissue was effectively protected, further suggesting that Mn@Pt 5’ efficiently eliminated MSU and inhibited damage to ankle joint tissue (Fig. 5I). Next, immunohistochemical staining demonstrated that following MSU stimulation, the AGA group showed increased expression of pro-inflammatory factors (TNF-α and IL-6), while the expression of anti-inflammatory factors (TGF-β and IL-10) was downregulated. The expression of inflammatory factors in the Mn group was comparable to that in the AGA group, while the Pt group presented reduced levels of TNF-α and IL-6 but did not significantly affect the levels of anti-inflammatory factors. Notably, higher doses of Mn@Pt micro-GC (Mn@Pt 5’) exhibited the most effective anti-inflammatory capacity (Fig. 5J, Supplementary Fig. 23). Moreover, the Mn@Pt 5’ treatment led to the highest levels of Arg-1 and the lowest levels of iNOS compared with the other treated groups, suggesting that Mn@Pt 5’ effectively promoted macrophage polarization towards the anti-inflammatory M2 phenotype (Fig. 5K–M). These outcomes were linked to the ability of Mn@Pt 5’ to efficiently decompose MSU and produce H2 to reduce inflammation in acute gout-affected joints, thereby assisting in relieving joint fever and swelling, minimizing pain, and safeguarding bone tissue. Gout also causes hepatic and renal functional impairment. Thus, the ability of Mn@Pt micro-GC to prevent such damage was evaluated. Blood biochemistry and H&E results indicated that the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Cr) significantly increased in the AGA group after 6 h of MSU injection, with notable liver and kidney damage (including inflammatory cell infiltration, enlarged liver fissures, and renal interstitial fibrosis). However, the liver and kidney function indicators and histomorphological structure in the Mn@Pt 5’ group returned to normal after 24 h of treatment (Fig. 5N–Q, Supplementary Figs. 24, 25A). These findings suggested that the effective UA degradability and anti-inflammatory properties of Mn@Pt micro-GC helped reduce the risk of liver and kidney damage in rats. Furthermore, the therapeutic effect appeared to be concentration-dependent within a safe dosage range (there were no abnormalities in the size or structure of the heart, spleen, or lungs across all groups) (Supplementary Fig. 25B). Consequently, a treatment dose of 5 mg/mL of Mn@Pt micro-GC was utilized in the following studies. Therapeutic evaluation of Mn@Pt micro-GC treatments in gouty arthritis To better simulate the process of gout attacks in the human body, we initially constructed an HUA model. After the rats were given hypoxanthine (500 mg/kg) via the oral route and potassium oxycyanates (150 mg/kg) via intraperitoneal (i.p.) injection for 7 consecutive days54, the UA levels in the serum were measured. Compared with that in the normal group, the UA level in the Model group was significantly elevated (Supplementary Fig. 26), confirming the successful establishment of the HUA model. Subsequently, MSU was injected into the ankle joints of the rats to mimic the development of human gout and create a gouty arthritis (GA) model. On the 8th day, treatments were applied to the ankle joint, with evaluation points set at 6, 24, 48, and 72 h. These rats were euthanized after 3 days of treatment (Fig. 6A). Similarly, the various symptoms of gout were not relieved in the GA/Mn group, while both the GA/Pt and GA/Mn@Pt groups showed certain therapeutic effects. Among them, the GA/Mn@Pt group performed the best therapeutic effects. Specifically, the GA/Mn@Pt group benefited from its urate oxidase-like activity, resulting in a significant decrease in UA levels in the rats after 6 h (Fig. 6B), while also protecting the ankle joint bone tissue and restoring the integrity of the cartilage and collagen fibers (Fig. 6F–I, K, Supplementary Fig. 29). Furthermore, the spontaneous release of H2 and Mn2+ from the Mn@Pt micro-GC transformed the overall microenvironment into an anti-inflammatory state (Fig. 6J, L–R, Supplementary Fig. 30), which helped reduce swelling, fever, and pain in the ankle joints of the rats (Fig. 6C–E, Supplementary Figs. 27, 28). Additionally, the damage to liver and kidney functions caused by gout was also reversed without causing damage to other organs (Fig. 6S–U, Supplementary Figs. 31, 32), suggesting that Mn@Pt micro-GC not only effectively alleviates acute gouty arthritis but also offered potential for long-term gout treatment, highlighting its possible application in clinical gout management.Fig. 6Therapeutic evaluation of Mn@Pt micro-GC in GA rats.A Schematic illustration of the therapeutic procedure used in the animal experiments (created in BioRender. Fei, G. (2026) https://BioRender.com/qurbiq8). B Effects of different treatments on lowering serum UA levels in GA rats (n = 4 samples). C Diameter of the ankle joints in GA rats at 72 h after Mn, Pt, or Mn@Pt micro-GC treatment (n = 4 samples). D Gait analysis of GA rats at 72 h after the administration of Mn, Pt, or Mn@Pt micro-GC. E Infrared thermographic images of GA rats after different treatments. F Micro-CT images of the ankle joints of rats subjected to different treatments. G–I BMD, BV/TV, and Tb.Sp of the ankle joints in the different groups after treatment (n = 4 samples). J Representative images of immunofluorescence staining for iNOS (red) and Arg-1 (green) in the ankle joints from different treatment groups. K H&E and SO/FG images of the ankle joints from different treatment groups. L Immunohistochemical staining images of TNF-α and IL-10 in the tali after administration of different treatments. M, N Statistical analysis of immunofluorescence staining for iNOS and Arg-1 in the ankle joints (n = 5 samples). O–R Effects of different treatments on the serum inflammatory cytokine levels in GA rats (n = 3 samples). S–U Hepatic and renal function tests of GA rats at 72 h after administration (n = 4 samples), including AST, ALT, and Cr. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Therapeutic evaluation of Mn@Pt micro-GC in GA rats. A Schematic illustration of the therapeutic procedure used in the animal experiments (created in BioRender. Fei, G. (2026) https://BioRender.com/qurbiq8). B Effects of different treatments on lowering serum UA levels in GA rats (n = 4 samples). C Diameter of the ankle joints in GA rats at 72 h after Mn, Pt, or Mn@Pt micro-GC treatment (n = 4 samples). D Gait analysis of GA rats at 72 h after the administration of Mn, Pt, or Mn@Pt micro-GC. E Infrared thermographic images of GA rats after different treatments. F Micro-CT images of the ankle joints of rats subjected to different treatments. G–I BMD, BV/TV, and Tb.Sp of the ankle joints in the different groups after treatment (n = 4 samples). J Representative images of immunofluorescence staining for iNOS (red) and Arg-1 (green) in the ankle joints from different treatment groups. K H&E and SO/FG images of the ankle joints from different treatment groups. L Immunohistochemical staining images of TNF-α and IL-10 in the tali after administration of different treatments. M, N Statistical analysis of immunofluorescence staining for iNOS and Arg-1 in the ankle joints (n = 5 samples). O–R Effects of different treatments on the serum inflammatory cytokine levels in GA rats (n = 3 samples). S–U Hepatic and renal function tests of GA rats at 72 h after administration (n = 4 samples), including AST, ALT, and Cr. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Therapeutic evaluation of Mn@Pt micro-GC treatments in neuropathic pain The encouraging inhibitory effect of Mn@Pt micro-GC on the CXCL5-neuronal CXCR2-TRPA1 axis observed in vitro prompted us to investigate its pain-relief effect in vivo. After the treatment of the rats with acute gout, their ankle joints were dissected and observed using SEM. Mn@Pt micro-GC still presented at the interface between the tibia and talus and was not fully reacted (Fig. 7B). To better illustrate the electrical stimulation of Mn@Pt micro-GC in vivo, a minimally invasive electrode was inserted into the ankle joints of the rats, followed by the injection of Mn@Pt micro-GC (Fig. 7A). The voltage showed a quality-dependent increase after the injection of Mn@Pt micro-GC at 200 s, indicating that it could adhere to the joint cavity and generate sustained electrical stimulation (Fig. 7C). However, Mn or Pt particles of the same mass did not produce similar phenomena (Supplementary Fig. 33). Moreover, this continuous electrical stimulation also caused a high charge on the surface of the tissue at the ankle joint (Supplementary Fig. 34). Immunohistochemical results revealed that the expression of CXCL5 in the AGA/Mn@Pt 5’ group at the ankle joint was significantly lower than that in the AGA group (Fig. 7D). This reduction was attributed to the MSU degradation capability of the Mn@Pt micro-GC, which decreased the source of stimulation that triggered pain signals. The dorsal root ganglion (DRG) is the primary center for the transmission of nociceptive signals, playing a crucial role in transmitting and regulating sensory functions, as well as receiving and conducting pain sensations55,56. It is particularly important in the occurrence and maintenance of acute and chronic pain, especially neuropathic pain, making the DRG a key target for pain treatment. The outcomes of the immunofluorescence staining and statistical analysis were consistent with our predictions. Owing to the substantial decrease in CXCL5, the levels of CXCR2 and TRPA1 in the AGA/Mn@Pt 5’ group were also notably lower (Fig. 7E–H). Furthermore, the somewhat less effective pain relief observed in the AGA/Pt or AGA/Mn@Pt 1’ group could be attributed to the inability of Pt to support electrical signal production, while a lower dosage of Mn@Pt 1’ may not provide a better therapeutic effect. Then, a further comparison was conducted to evaluate the differences in pain relief between the Mn and Pt mixture, exogenous electrical stimulation and the Mn@Pt micro-GC. Electrical stimulation (0.3 V, 30 min) was administered to the ankle joints of acute gout rats, followed by a second stimulation after a 6-h interval (Fig. 7I). After 24 h, the gait information of the rats was recorded, and the rats were then euthanized to collect DRG for immunofluorescence staining. The gait of the AGA/ES group was similar to that of the AGA/Mn@Pt group, with both exhibiting longer stride and step lengths than the AGA and AGA/Mn+Pt group did, as well as shorter front/hind paw prints (Fig. 7J, K). Furthermore, the expression of CXCR2 and TRPA1 in the DRG was significantly lower in the AGA/Mn+Pt, AGA/ES and AGA/Mn@Pt treatment groups than in the AGA group, with the AGA/Mn@Pt group showing a more pronounced inhibitory effect than the AGA/Mn+Pt group did (Fig. 7L–O). These findings collectively suggested that Mn@Pt micro-GC reduced the expression of CXCL5 by decreasing macrophage stimulation from MSU, while continuous electrical stimulation diminished the binding of CXCL5 to CXCR2, leading to decreased TRPA1 activation and Ca2+ influx (Fig. 7P). More importantly, the suppression of gouty pain was closely related to the electrical stimulation it released. Although the physical components in the Mn+Pt treatment group reduced UA levels and alleviated heat and swelling in the ankle joint (Supplementary Fig. 35), their ability to relieve pain was weaker, highlighting the significant role of electrical stimulation in treating inflammatory pain. Therefore, the strong inhibitory effect of Mn@Pt micro-GC on the CXCL5-neuronal CXCR2-TRPA1 axis effectively blocked the transmission of pain signals, which aided in the relief of joint pain and promoted the treatment of gouty arthritis. Similarly, Mn@Pt micro-GC performed the same therapeutic effect on a GA model induced by HUA. After the accumulated MSU was decomposed by Pt or Mn@Pt micro-GC, the expression of CXCL5 in the ankle joint decreased (Supplementary Fig. 36A). Consequently, the levels of CXCR2 and TRPA1 in the DRG of both treatment groups were reduced, with Mn@Pt micro-GC exhibiting the best inhibitory effect on the CXCL5-neuronal CXCR2-TRPA1 axis (Supplementary Figs. 36B–E), further validating its ability to block pain signal transmission.Fig. 7Pain relief effects of Mn@Pt micro-GC in AGA rats.A Schematic diagram of monitoring electricity released from Mn@Pt micro-GC in the ankle joints of rats. B SEM images of the tibial surface in AGA rats after treatment with the Mn@Pt micro-GC. C Voltage variation curves after introducing different amounts of Mn@Pt micro-GC to the ankle joint cavity. D Immunohistochemical staining images of CXCL5 in the tali after administration of different treatments. E, F Representative images and G, H statistical analysis of immunofluorescence staining for CXCR2 (red) and TRPA1 (purple) in the DRG (n = 5 samples). I Schematic diagram of external electrical stimulation in vivo. J, K Gait analysis of AGA rats at 24 h after the administration of Mn@Pt micro-GC, Mn+Pt or external electrical stimulation (n = 6 samples). L, M Statistical analysis and N, O representative images of immunofluorescence staining for CXCR2 (red) and TRPA1 (purple) in the DRG after treatment with Mn@Pt micro-GC, Mn+Pt, or external electrical stimulation (n = 5 samples). P Schematic diagram of Mn@Pt micro-GC-induced inhibition of the CXCL5-neuronal CXCR2-TRPA1 axis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test, and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Schematic diagram of A, I, and P were created in BioRender. Fei, G. (2026) https://BioRender.com/ai1n9un. Pain relief effects of Mn@Pt micro-GC in AGA rats. A Schematic diagram of monitoring electricity released from Mn@Pt micro-GC in the ankle joints of rats. B SEM images of the tibial surface in AGA rats after treatment with the Mn@Pt micro-GC. C Voltage variation curves after introducing different amounts of Mn@Pt micro-GC to the ankle joint cavity. D Immunohistochemical staining images of CXCL5 in the tali after administration of different treatments. E, F Representative images and G, H statistical analysis of immunofluorescence staining for CXCR2 (red) and TRPA1 (purple) in the DRG (n = 5 samples). I Schematic diagram of external electrical stimulation in vivo. J, K Gait analysis of AGA rats at 24 h after the administration of Mn@Pt micro-GC, Mn+Pt or external electrical stimulation (n = 6 samples). L, M Statistical analysis and N, O representative images of immunofluorescence staining for CXCR2 (red) and TRPA1 (purple) in the DRG after treatment with Mn@Pt micro-GC, Mn+Pt, or external electrical stimulation (n = 5 samples). P Schematic diagram of Mn@Pt micro-GC-induced inhibition of the CXCL5-neuronal CXCR2-TRPA1 axis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by using One-way ANOVA analysis with Tukey’s post hoc test, and ns represents no significant difference. The data are presented as the means ± SD. Source data are provided as a Source Data file. Schematic diagram of A, I, and P were created in BioRender. Fei, G. (2026) https://BioRender.com/ai1n9un. The release of CXCL5 in the ankle joint activates CXCR2 in neurons, which further promotes the release of the neuropeptides calcitonin gene-related protein (CGRP) and substance P (SP) at nerve endings23. These neuropeptides can act on receptors expressed on blood vessels, thereby promoting the accumulation of neutrophils in inflammatory joints53. Therefore, to further elucidate the role of Mn@Pt micro-GC in the treatment of gout, we investigated whether Mn@Pt micro-GC could affect the expression of neuropeptides and the infiltration of neutrophils in the ankle joints of AGA rats. Immunofluorescence staining revealed that after treatment with Mn@Pt micro-GC, the expression of CGRP and SP in the ankle joints of the rats was suppressed (Supplementary Fig. 37A–D). Moreover, compared with that in the AGA group, neutrophil infiltration in the Mn@Pt micro-GC treatment group was inhibited (Supplementary Fig. 37E, F), suggesting that Mn@Pt micro-GC can disrupt the vicious cycle of mutual promotion between inflammatory factors and neuropeptides, which is beneficial for the treatment of gouty arthritis. Safety assessment In previous treatments, Mn@Pt micro-GC did not cause obvious damage to the ankle joint or other organs. To further evaluate its in vivo biosafety, we injected an equal amount of Mn@Pt micro-GC into the ankle joints of healthy rats and assessed its biodistribution in the heart, liver, spleen, lungs, and kidneys on day 3. ICP-OES results revealed that the Mn and Pt levels in these organs did not differ significantly from those in normal rats, and H&E staining images also revealed no obvious tissue damage (Supplementary Fig. 38A–C). Additionally, tissues from the ankle joints of both the Normal group and the Mn@Pt group were further evaluated on 1, 3, 5, 7, 10 and 15 days. The contents of metal elements (Mn or Pt) in the ankle joints showed no significant differences compared to normal rats (Supplementary Fig. 38D, E). Moreover, membrane potential staining at the corresponding time points indicated that Mn@Pt micro-GC still induced a great change in the membrane potential of the ankle joint for over 3 days (Supplementary Fig. 38F, G). These results suggested that Mn@Pt micro-GC sustained its therapeutic effects at the ankle joint for an extended period and subsequently underwent gradual degradation over time. To avoid the impact of Mn@Pt micro-GC degradation on safety assessment, we subsequently compared the ankle joint condition between the Mn@Pt group and the Normal group at 6 h. The results showed that the Mn@Pt micro-GC did not cause swelling, heat or gait disturbances in the ankle joints of the rats, nor did it lead to tissue damage or inflammatory responses in the ankle joints (Supplementary Fig. 38H–L). These results collectively demonstrated the good biocompatibility of Mn@Pt micro-GC in vivo, indicating promising potential for its application in treating inflammatory diseases. Discussion In summary, Mn@Pt micro-GC were designed and constructed to address the various challenges associated with gout treatment. Mn@Pt micro-GC not only facilitated the degradation of UA through the urate oxidase-like activity of Pt but also decomposed H2O2 by Mn2+ generated from spontaneous reactions, working in conjunction with H2 to alleviate inflammatory responses. As revealed by the cellular experiments, Mn@Pt micro-GC effectively mitigated UA-induced oxidative damage and promoted the removal of H2O2. Moreover, it regulated macrophage phenotype polarization and decreased the expression of inflammatory factors, thereby improving the inflammatory response. The RNA sequencing results further suggested that, besides the inherent catalytic degradation properties of the Mn@Pt micro-GC that reduced the generation of pain signals, the continuous electrical stimulation from it inhibited pain signal transmission along the CXCL5-neuronal CXCR2-TRPA1 axis by diminishing the interaction between cytokines and their receptors. After injecting Mn@Pt micro-GC into the joint cavity of gouty rats, a reduction in UA levels was observed, along with alleviated joint swelling, fever, and inflammatory response. Notably, Mn@Pt micro-GC effectively suppressed the generation and transmission of pain signals, demonstrating superior analgesic effects compared with exogenous electrical stimulation. It also broke the vicious cycle of mutual promotion between inflammatory factors and neuropeptides, which was beneficial for the treatment of gouty arthritis. Our research highlights the advantages of this multifunctional metal galvanic cell system in treating gouty arthritis, offering a strategy for bone-nerve-based therapy of joint inflammation. However, although the Mn@Pt micro-GC quickly and promptly addresses multiple challenges in the treatment of gouty arthritis, its local minimally invasive drug delivery method is not suitable for patients who already have joint diseases, coagulation dysfunction, or skin infections at the joint site. Therefore, while retaining the multiple therapeutic effects of the metal galvanic cell, further development of more universal treatment methods for gout is our future direction. For example, in these patients, early and low-intensity intervention through non-invasive drug delivery methods (such as hydrogel microneedles or patches) can be used to delay the progression of gout or prevent its occurrence. This combination of non-invasive and minimally invasive approaches also helps to build a bridge between disease prevention and treatment, promoting the integration of prevention and therapy. Methods Ethical Statement Male Sprague Dawley (SD) rats (6-8 weeks old) were purchased from Hangzhou Qizhen Experimental Animal Technology Co., Ltd. All animal experiments were performed in compliance with the relevant laws and approved by the Institutional Animal Care and Use Committee of Soochow University (No. ECSU. 202410A0472). Materials Mn microparticles (99.9%, two size: ~10 and ~50 μm) were purchased from Beijing Hawk Science & Technology Co., Ltd. Chloroplatinic acid hexahydrate (H2PtCl6·6H2O) was purchased from Sinopharm Chemical Reagent Co., Ltd. PEG400 was purchased from Chinasun Specialty Products Co., Ltd. Monosodium urate (MSU, U8291) and 4,6-diamino-2-phenyl indole (DAPI) solution (C0060) were purchased from Beijing Solarbio Science & Technology Co., Ltd. Hypoxanthine (H301755) and potassium oxycyanates (P137112) were purchased from Aladdin Reagent Co., Ltd. Mouse mononuclear macrophage leukemia RAW264.7 cell line was purchased from the American Type Culture Collection. Mouse embryonic osteoblast precursor cell line (MC3T3-E1) was purchased from Shanghai Fuheng Biotechnology Co., Ltd. Rat adrenal pheochromocytoma (PC-12) cell was purchased from Wuhan Pricella Biotechnology Co., Ltd. Fetal bovine serum was purchased from Biosharp Biotechnology Co., Ltd. Lipopolysaccharide (LPS) and uric acid (UA, U2625) were purchased from Sigma-Aldrich. iNOS polyclonal antibody (18985-1-AP), Arg-1 polyclonal antibody (16001-1-AP), TRPA1 polyclonal antibody (19124-1-AP), Substance P polyclonal antibody (13839-a-AP) and GAPDH monoclonal antibody (60004-1-Ig) were purchased from Proteintech Group, Inc. CGRP monoclonal antibody (D5R8F) was purchased from Cell Signaling Technology. PE anti-mouse CD86 antibody (105008) and FITC anti-mouse F4/80 antibody (157310) were purchased from Biolegend. CXCR2 antibody (CXCR2-201AP) was purchased from Thermo Fisher Scientific. CXCL5 antibody (DF9919) was purchased from Affinity Biosciences Pty Ltd. Fluo-4 AM detection kit (S1060) was purchased from Beyotime. TRIzol reagent was purchased from Invitrogen Corporation. Preparation of Mn@Pt micro-GC Mn@Pt micro-GC with various mass ratios of positive (Pt) and negative (Mn) electrodes were prepared by gradually adding anhydrous ethanol solutions containing 50 mg of Mn microparticles (~50 μm) to different concentrations of PtCl62−. After 3 h of magnetic stirring at room temperature, the Mn@Pt micro-GC were further refined through centrifugation (1006 g, 5 min) to remove the supernatant, and washed with anhydrous ethanol. Finally, the Mn@Pt micro-GC was resuspended in anhydrous ethanol for further characterization and utilization. As determined by ICP-OES, varying the input mass ratios of PtCl62⁻ to Mn (0.32%, 1.6%, 4.0%, and 8.0%) allowed the preparation of a series of Mn@Pt micro-GC structures with different Pt loadings (0.10%, 0.16%, 0.20%, and 0.48%, respectively). Characterization of the Mn@Pt micro-GC After the Mn@Pt micro-GC (with various mass ratios) was dried in an oven at 37 °C, gold was sprayed at 30 mA for 30 s on it. The Mn@Pt micro-GC was observed by scanning electron microscopy (SEM, ZEISS G500, Germany). Elemental mapping was also employed to characterize the Mn@Pt micro-GC and analyze its elemental composition. X-ray diffraction (XRD) pattern revealed the presence of metallic elements. Electrochemical characterization of Mn@Pt micro-GC The voltage and Tafel slope of the Mn@Pt micro-GC (with various mass ratios) were measured on an electrochemical workstation using a three-electrode system. A graphite electrode and an Ag/AgCl electrode were used as the counter electrode and the reference electrode, respectively. A glassy carbon electrode coated with Mn@Pt micro-GC was used as the working electrode. Physiological saline was used as the electrolyte for tests. The voltage values were converted from E(Ag/AgCl) to E(RHE) according to the following formula: E(RHE) = E(Ag/AgCl) + 0.194 + 0.0592 × pH57. The electric current of the Mn@Pt micro-GC (with various mass ratios) was assessed on an electrochemical workstation using a two-electrode system. A graphite electrode was used as the counter electrode, and a glassy carbon electrode loaded with Mn@Pt micro-GC was used as the working electrode. Physiological saline was used as the electrolyte for tests. H2 release The water displacement method was used to quantitatively measure the amount of released H2, as detailed below: n(H2) = V0/22.4, V0: H2 volume under standard conditions to be determined. UA clearance test The UA (with a characteristic absorption peak at 292 nm) scavenging ability of Mn@Pt micro-GC (compared between different mass ratios or compared with that of Mn, Pt, and Mn+Pt) was determined via a UV-vis spectrophotometer. 25 μg/mL of UA and 1 mg/mL Mn@Pt micro-GC were co-incubated, and the absorbance of UA at 292 nm was measured at 1, 2, 4, 8, and 24 h, respectively. ROS scavenging The ROS scavenging capacity of the Mn@Pt micro-GC was evaluated using •OH (oxTMB as an indicator with a characteristic absorption peak at 652 nm), •ABTS+ (with a characteristic absorption peak at 738 nm) and the titanium (IV) oxysulfate colorimetry (with a characteristic absorption peak at 415 nm). To produce oxTMB, a mixture of 19.2 mg/mL of TMB, 2 mg/mL of Fe2+, and 10 mM of H2O2 was prepared. Then, 0.8 mg/mL of oxTMB was introduced to different concentrations of Mn@Pt micro-GC (0, 12.5, 25, 50, and 100 μg/mL) to react for 30 min. To obtain •ABTS+, 3.75 mg/mL of ABTS and 1.5 mg/mL of potassium persulfate (K2S2O8) were incubated overnight in the dark. Subsequently, 0.2 mg/mL of •ABTS+ was mixed with different mass ratios or different concentrations of Mn@Pt micro-GC (0, 12.5, 25, 50, and 100 μg/mL) to react for 30 min. The absorbance changes at 652 nm and 738 nm were measured using a UV-vis spectrophotometer. In addition, 4 mM H2O2 solution and 200 μg/mL Mn@Pt micro-GC (compared with different mass ratios or with Mn or Pt) were mixed. After 2 minutes of reaction, the remaining Mn@Pt micro-GC was removed, and 9.4 mg/mL of Ti(SO4)2 was added to react with the remaining H2O2 solution to form a yellow peroxidation-Ti complex precipitate. The supernatant was then separated by centrifugation at 1006 g, and concentrated sulfuric acid (2 M) was added to the precipitate until the precipitate was fully dissolved. Finally, the H2O2 scavenging ability of the Mn@Pt micro-GC was detected at ~ 415 nm via a UV-vis spectrophotometer. Cell culture RAW264.7 cells and PC-12 cells were cultured in standard cell culture medium, while MC3T3-E1 cells were cultivated in minimum essential medium alpha containing 10% fetal bovine serum and 1% penicillin/streptomycin antibiotics. All the cells were cultured under 5% CO2 at 37 °C. Cytotoxicity test RAW264.7 cells, PC-12 cells, and MC3T3-E1 cells were inoculated into a 96-well plate (approximately 1 × 104 cells per well) and incubated overnight. Later, these cells were treated with Mn@Pt micro-GC at different concentrations (0, 6.25, 12.5, 25, 50, and 100 μg/mL) for 24 h. Finally, the standard methyl thiazolyl tetrazolium (MTT) assay was used to detect the viability of the cells. Cellular UA clearance test RAW264.7 cells were seeded in a 96-well plate (approximately 1 × 104 cells per well) and incubated overnight. Then, these cells were treated with 20 mg/mL of UA and 50 μg/mL of Mn@Pt micro-GC (UA-treated, UA/Mn-treated and UA/Pt-treated as the control) for 24 h. Subsequently, the MTT assay was used to detect the viabilities of the cells. Cellular ROS scavenging RAW264.7 cells were seeded in a 24-well plate (approximately 5 × 104 cells per well) and incubated overnight. Then, these cells were treated with 250 ng/mL of LPS and 50 μg/mL of Mn@Pt micro-GC (LPS-treated, LPS/Mn-treated, and LPS/Pt-treated as the control) for 12 h. Subsequently, the cells were stained with DCFH-DA for 30 min, which possessed the capacity to clear ROS. After the cells were washed, a confocal laser scanning microscope (CLSM, Zeiss, Germany) was used to observe the degree of ROS staining. Additionally, fluorescence was analyzed via flow cytometry (C6 Plus Flow Cytometry, BD Accuri, USA). Furthermore, [Ru(dpp)3]Cl2 was employed to detect the generation of oxygen (O2). RAW264.7 cells were treated with 200 μM H2O2 and 50 μg/mL of Mn@Pt micro-GC (H2O2-treated, H2O2/Mn-treated, and H2O2/Pt-treated as the control) for 24 h. Afterward, the [Ru(dpp)3]Cl2 (50 μM) was used to stain for 40 min. Following washing cells, the CLSM was utilized to observe the production of O2. Macrophage phenotype regulation RAW264.7 cells were seeded in a 24-well plate and incubated overnight (approximately 5 × 104 cells per well). Then, these cells were treated with 250 ng/mL of LPS and 50 μg/mL of Mn@Pt micro-GC (LPS-treated, LPS/Mn-treated, and LPS/Pt-treated as the control) for 12 h. M1 and M2 macrophages were labeled with iNOS and Arg-1 overnight at 4 °C, respectively. Following that, an Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody was used, and the fluorescence results were observed via CLSM. Additionally, F4/80 and CD86 were used to mark the M1 macrophages and the fluorescence was analyzed via C6 Plus flow cytometry. Enzyme-linked immunosorbent assay (ELISA) The expression of TNF-α, IL-6, IL-10, and TGF-β in the cell supernatant and serum was detected via ELISA kits. Western blotting RAW264.7 cells were seeded in a 6-well plate (approximately 3×105 cells per well) and incubated overnight. Then, these cells were treated with 1 mg/mL of MSU and 50 μg/mL of Mn@Pt micro-GC (MSU-treated, MSU/Mn-treated, and MSU/Pt-treated as the control) for 24 h. Protease and phosphatase inhibitors were added to extract the protein during the cell lysis, after which a BCA protein assay kit was used for quantification. The extracted proteins were mixed with SDS-loading buffer, boiled at 95 °C, and resolved on 6% or 10% SDS-PAGE gels. After 90 minutes of electrophoresis at 150 V, the proteins were transferred to nitrocellulose membrane at 300 mA for 90 min. The membranes were blocked with 5% BSA solution at room temperature for 2 h. Next, the membranes were incubated at 4 °C overnight with primary antibodies against the following proteins: CXCL5 and GAPDH. On the second day, the membranes were washed with PBST 3 times and incubated with the corresponding secondary antibody for 2 h. Finally, DNA electrophoresis gel imager was used to visualize the membranes. The PC-12 cells were seeded in a 6-well plate (approximately 3 × 105 cells per well) and incubated overnight. Then, these cells were treated with the corresponding supernatants of RAW264.7 cells (Ctrl-CM, MSU-CM, MSU/Mn-CM, MSU/Pt-CM and MSU/Mn@Pt-CM). Besides, PC-12 cells were treated with the supernatant of RAW264.7 cells (MSU-CM), and then treated with 100 μg/mL of Mn@Pt micro-GC for 24 h (electrical stimulation (ES)-treated as the control, 0.3 V, 10 Hz, 30 min). The other operations were the same as before, and the primary antibodies included CXCR2, TRPA1, and GAPDH. Intracellular Ca2+ detection PC-12 cells were seeded in a 24-well plate and incubated overnight (approximately 5×104 cells per well). Then, these cells were treated as same as described above. After the cultivation, the PC-12 cells were stained with Fluo-4 AM (2 μM) for 20 min, and the fluorescence was assessed via C6 Plus flow cytometry. Membrane potential staining PC-12 cells were seeded in a 24-well plate (approximately 5 × 104 cells per well) and incubated overnight. Then, these cells were treated with different concentrations of Mn@Pt micro-GC (0, 0.1, 0.5, and 1 mg/mL). Subsequently, the cells were stained with RH 414 for 30 min, which showed the situation of membrane potential. After the cells were washed, CLSM was used for observation. RNA sequencing PC-12 cells were seeded in a middle dish (approximately 8 × 105 cells per well) and incubated overnight. Then, these cells were treated with the supernatant of RAW264.7 cells (MSU-CM) and 100 μg/mL of Mn@Pt micro-GC for 24 h (ES-treated as the control, 0.3 V, 10 Hz, 30 min). Next, total RNA was extracted from the cells using TRIzol reagent according to the vendor’s instructions. The genes with the parameter of P value < 0.05 and absolute fold change ≥ 2 were considered as differentially expressed genes (DEGs). The functional enrichment analysis of DEGs was performed based on the gene ontology (GO) analysis and kyoto encyclopedia of genes and genomes (KEGG) analysis. Among them, a pathway or process with P value < 0.05 was considered to be significantly enriched. Additionally, the gene set enrichment analysis (GSEA) was performed to show the specific situation of the enriched pathways. Preparation of acute gouty arthritis and hyperuricemia models All animal experiments in this study were carried out in accordance with the guidelines approved by the Laboratory Animal Center of Soochow University. An acute gouty arthritis (AGA) rat model was established by injecting MSU (20 mg/mL, 50 μL) into the ankle joints of six-week-old SD male rats. These rats were randomly divided into 6 groups (n = 4 per group): Sham (intra-articular injection of normal saline, 100 μL), AGA (intra-articular injection of MSU and PEG 400 (50 μL)), AGA/Mn (intra-articular injection of MSU and Mn (5 mg/mL, 50 μL)), AGA/Pt (intra-articular injection of MSU and Pt (10 μg/mL, 50 μL)), AGA/Mn@Pt 1’ (intra-articular injection of MSU and Mn@Pt micro-GC (1 mg/mL, 50 μL)) and AGA/Mn@Pt 5’ (intra-articular injection of MSU and Mn@Pt micro-GC (5 mg/mL, 50 μL)). Among them, Mn, Pt, or Mn@Pt micro-GC was mixed evenly with sterilized PEG 400 before use, and the amount of injected Pt was consistent with the therapeutic dose of Pt in the Mn@Pt micro-GC. For the detailed procedure of intra-articular injection, we used a 30-gauge (30 G) needle and injected different drugs after MSU was administered. The needle was inserted from the anterior depression of the ankle joint into the joint space, with an insertion depth of approximately 0.4–0.5 cm. Edema degree analysis, thermal imaging, gait analysis, UA level analysis, and liver and kidney function analysis were performed at 6 and 24 h. After 24 h, the rats were euthanized, and their ankle joints and dorsal root ganglia (DRG) were collected for further experiments. In addition, the hearts, livers, spleens, lungs, and kidneys were harvested for biosafety assessments. The six-week-old SD male rats were given hypoxanthine (500 mg/kg) via the oral route and potassium oxycyanates (150 mg/kg) via i.p. injection for 7 consecutive days to establish the hyperuricemia (HUA) model13,54. On the 8th day, MSU (20 mg/mL, 50 μL) was injected into the ankle joints of the rats to simulate the progression of gout in the human body, resulting in a gouty arthritis (GA) rat model. These rats were then randomly divided into 5 groups (n = 4 per group): Normal (without any treatment), GA (intra-articular injection of MSU and PEG 400 (50 μL)), GA/Mn (intra-articular injection of MSU and Mn (5 mg/mL, 50 μL)), GA/Pt (intra-articular injection of MSU and Pt (10 μg/mL, 50 μL)) and GA/Mn@Pt (intra-articular injection of MSU and Mn@Pt micro-GC (5 mg/mL, 50 μL)). The specific administration method and operational details were consistent with the above, and other procedures were conducted as previously described at designated time points (6, 24, 48, and 72 h). The rats were sacrificed at 11 days, and their ankle joints and DRG were collected for further experiments. Additionally, the hearts, livers, spleens, lungs, and kidneys were harvested for biosafety assessments. Additionally, to further investigate the inhibitory ability of Mn@Pt micro-GC on the bone-neural axis, an AGA rat model was established by injecting MSU (20 mg/mL, 50 μL) into the ankle joints of six-week-old SD male rats. These rats were randomly divided into 4 groups (n = 6 per group): AGA (intra-articular injection of MSU and PEG 400 (50 μL)), AGA/Mn+Pt (intra-articular injection of MSU, Mn (10 mg/mL, 25 μL) and Pt (20 μg/mL, 25 μL)), AGA/Mn@Pt (intra-articular injection of MSU and Mn@Pt micro-GC (5 mg/mL, 50 μL)), and AGA/ES (intra-articular injection of MSU and electrical stimulation-treated, 0.3 V, 10 Hz, 30 min each). The specific administration method and operational details were consistent with the above, and other procedures were conducted as previously described at designated time points. The rats were sacrificed at 24 h, and their DRG were collected for further experiments. Gait analysis The front paws of the SD rats were dipped in blue ink, while their hind paws were coated with red ink. The rats then walked from one side of the white cardboard to the other to record their gait. Prior to the formal experiment, all the rats received pre-training to ensure that they could run the whole course within 10 seconds. Only the rats that passed the training session were used in the formal experiment. Micro-CT Ankle joints of rats euthanized were scanned via micro-CT (80 kV, 300 μA, Skyscan 1174, Belgium). Moreover, the bone parameters BMD, BV/TV, Tb.N and Tb.Sp were separately measured. Histological staining For immunohistochemical staining, the ankle joints of euthanized rats were fixed in 4% paraformaldehyde for at least 48 h and then soaked in 10% EDTA for 30 days. The tissue slices were prepared via paraffin embedding of decalcified tissue and stained with H&E, safranin O/fast green, TNF-α, IL-6, IL-10, TGF-β, and CXCL5 to observe the healing of synovial area injuries and the alleviation of inflammation. Hearts, livers, spleens, lungs, and kidneys were validated for biosafety through H&E. For immunofluorescence staining, the ankle joints were stained with primary antibodies (including iNOS and Arg-1), while the DRG were stained with primary antibodies (including CXCR2, TRPA1, and NeuN), along with corresponding secondary antibodies to visualize the inflammatory state and the effectiveness of pain relief from the treatment. Statistics and Reproducibility A minimum of three biological replicates was used for quantitative analysis. The experiments, such as scanning electron microscopy, western blot, immunofluorescence staining, and H&E staining, were repeated three times. All the statistical analyses were performed by GraphPad Prism 8.0.2. The results were expressed as the mean ± standard deviation (SD). Significant differences between the two groups were determined via two-tailed unpaired t-test. One-way ANOVA analysis with Tukey’s post hoc test was employed for the significant differences among multiple comparisons. Ns represented no significant difference and the P value of <0.05 was considered statistically significant. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supporting Information Reporting Summary Transparent Peer Review file Supporting Information Reporting Summary Transparent Peer Review file Source data Source Data Source Data